Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412) Diefenbach, C. S., Hong, F., Cohen, J. B., Robertson, M. J., Ambinder, R. F., Fenske, T. S., Advani, R. H., Kahl, B. S., Ansell, S. AMER SOC HEMATOLOGY. 2015
View details for Web of Science ID 000368019002022